22/02/2026
Gastroparesis can occur in people with scleroderma due to impaired motility of the stomach muscles. As a result, symptoms of delayed gastric emptying may appear alongside the skin, vascular, and connective tissue involvement characteristic of scleroderma. In such cases, overlapping manifestations can increase clinical complexity, particularly because digestive symptoms may mimic or worsen autoimmune disease activity.
Gastroparesis is characterized by delayed stomach emptying in the absence of mechanical obstruction. In individuals with scleroderma, the digestive muscles and nerves can be affected, leading to slowed gastric motility. Common symptoms include nausea, early satiety, bloating, vomiting, abdominal pain, and unintentional weight loss. Because fatigue, reduced appetite, and gastrointestinal discomfort are also frequent in scleroderma, distinguishing gastroparesis-related symptoms from general disease activity is essential.
The severity and presentation of gastroparesis in scleroderma vary. Early signs may include mild bloating, fullness after small meals, and intermittent nausea. In more advanced cases, persistent vomiting, dehydration, and significant weight loss can occur. Managing these symptoms often requires a combination of dietary adjustments, medications, and sometimes procedural interventions to improve gastric emptying.
Diagnosis typically involves clinical evaluation, including symptom assessment, medical history, and consideration of other contributing factors such as medications or diabetes. Testing may include gastric emptying studies, imaging, and lab assessments. Interpretation can be more challenging in scleroderma patients, since overlapping autoimmune symptoms may obscure the presentation. Collaboration between gastroenterologists and rheumatologists is often necessary for accurate assessment and optimal management.
Treatment of gastroparesis in people with scleroderma generally focuses on symptom relief, nutritional support, and enhancing gastric motility. Dietary modifications, such as small frequent meals, low-fat and low-fiber foods, and liquid-based nutrition, can be helpful. Medications that stimulate gastric motility or reduce nausea may be prescribed. In severe cases, enteral feeding or other interventions may be required. Close monitoring alongside ongoing scleroderma care is important to maintain nutritional status and quality of life.
Overall, living with both scleroderma and gastroparesis can be challenging. Nevertheless, early recognition, careful management, and individualized care can significantly improve outcomes. If new or worsening digestive symptoms develop, prompt evaluation by a healthcare professional is strongly recommended.
References:
Arnett, F. C., & Steen, V. D. (2013). Gastrointestinal involvement in systemic sclerosis. Rheumatic Disease Clinics of North America, 39(2), 261–278.
Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013). Clinical guideline: Management of gastroparesis. The American Journal of Gastroenterology, 108(1), 18–37.
Johns Hopkins Medicine. (2022). Scleroderma and the digestive system. Johns Hopkins Scleroderma Center.
Disclaimer: This post is for educational and awareness purposes only and should not be considered medical advice. For personal health concerns or symptoms, please consult a qualified healthcare professional.
